Skip to Content

Tag: neb-meds


ABC Plus makes bid to revive neb-med biz

December 14, 2018Theresa Flaherty, Managing Editor

FORT PAYNE, Ala. - An increase in hospital readmissions for COPD patients could open the door for HME providers to re-enter a nebulizer medication market that has been dominated by national providers, says Marcus Kruk.“There was a full complement of care that used to exist when reimbursements were good,” said Kruk, national sales and marketing director and business development for ABC Plus, an independent respiratory medication pharmacy. “Now, patients are having difficulty finding...

ABC Plus, COPD, neb-meds, Nebulizers

Read Full Articlered right arrow icon

Also Noted

OIG: Lincare mostly complied with neb-med policies

December 21, 2017HME News Staff

CLEARWATER, Fla. - Lincare Pharmacy Services generally complied with Medicare requirements when billing for inhalation drugs, according to a new report from the Office of Inspector General. Of 100 claim lines sampled, three did not comply because the beneficiaries medical records did not support medical necessity, resulting in $48 in overpayments. The OIG recommends that Lincare ensure that medical necessity is adequately supported in medical records before billing Medicare. Lincare concurred.

Lincare, neb-meds

Read Full Articlered right arrow icon

Specialty Providers

ASP: Winners, losers, audits

October 25, 2013Theresa Flaherty, Managing Editor

BALTIMORE - With few exceptions, the average sales price (ASP) figures for nebulizer medications don't change much from quarter to quarter. That doesn't mean the market is stagnant, says Wayne Vega, senior vice president of the Inhalation Drug Group. He recently offered HME News his take on the fourth quarter numbers—and the market.WinnersBudesonide (J7626) increased 85 cents, to $5.95 per dose. The entry of another generic version of the drug into the market earlier this year didn't have the...

Average Sales Price, Budesonide, neb-meds

Read Full Articlered right arrow icon

Also Noted

ASP: Budesonide gets big boost

September 10, 2013HME News Staff

BALTIMORE - Things are looking up for several respiratory medications in the latest average sales price (ASP) figures. For the fourth quarter 2013, budesonide (J7626) took the biggest leap, up 85 cents to $5.95 per dose. Also getting an increase: brand name drugs Brovana (J7605) and Perforomist (J7606), which saw increases of 12 cents and nearly 39 cents per dose. Pricing stayed relatively flat for albuterol (J7613) and ipratropium (J7644) were both hovering around 12 cents per dose.

Albuterol, ASP Figures, Budesonide, neb-meds

Read Full Articlered right arrow icon


IDG offers Ritedose of help

May 7, 2013Liz Beaulieu, Editor

SOMERVILLE, N.J. - It's not easy being a smaller provider of nebulizer medications in the world of “Big Pharma.”That's why Inhalation Drug Group (IDG), a group purchasing organization, has rolled out a program targeting these smaller providers, giving them access to volume discount pricing, extended terms and sampling programs.“We're reaching out to the smaller end, because they're almost the more important players,” said Wayne Vega, senior executive vice president of IDG...

Group purchasing, Home Medical Equipment, neb-meds

Read Full Articlered right arrow icon

Specialty Providers

Prices, audits stay the course

April 23, 2012Theresa Flaherty, Managing Editor

BALTIMORE - Brand-name Brovana took a hit in the latest average sales price (ASP) figures for nebulizer medications, but otherwise there were few major changes.The long-acting beta agonist Brovana (J7605) decreased 24 cents to $5.11 per dose in the latest figures, released in March.Between the lower reimbursement and a price increase from the manufacturer, you won't see many providers supplying the drug, said Sam Jarczynski, who blames market consolidation for the change.“There are so few respiratory...

Albuterol, Average Sales Prices, Brovana, Budesonide, neb-meds, Perforomist

Read Full Articlered right arrow icon